Stock Track | PEGBIO CO-B Soars 10.69% Intraday on Lock-Up Extension and Clinical Milestone

Stock Track04-29

PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.

The sharp rise appears driven by two key positive developments. First, the company announced that cornerstone investors have voluntarily agreed to extend their lock-up period, demonstrating strong confidence in PEGBIO CO-B's future prospects based on its technological R&D capabilities and progress in key clinical milestones. Second, market focus has been redirected to the company's circRNA-LNP technology platform after its core pipeline candidate, CR059, was selected as a Late Breaking Abstract at the American Diabetes Association's Scientific Sessions, highlighting the new possibilities of its ultra-long-acting GLP-1 technology pathway for metabolic diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175159870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 13:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175159870","market":"nz","top_or_hot":-1,"title":"Stock Track | PEGBIO CO-B Soars 10.69% Intraday on Lock-Up Extension and Clinical Milestone","media":"Stock Track","content":"<p>PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.</p><p>The sharp rise appears driven by two key positive developments. First, the company announced that cornerstone investors have voluntarily agreed to extend their lock-up period, demonstrating strong confidence in PEGBIO CO-B's future prospects based on its technological R&D capabilities and progress in key clinical milestones. Second, market focus has been redirected to the company's circRNA-LNP technology platform after its core pipeline candidate, CR059, was selected as a Late Breaking Abstract at the American Diabetes Association's Scientific Sessions, highlighting the new possibilities of its ultra-long-acting GLP-1 technology pathway for metabolic diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PEGBIO CO-B Soars 10.69% Intraday on Lock-Up Extension and Clinical Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PEGBIO CO-B Soars 10.69% Intraday on Lock-Up Extension and Clinical Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 13:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.</p><p>The sharp rise appears driven by two key positive developments. First, the company announced that cornerstone investors have voluntarily agreed to extend their lock-up period, demonstrating strong confidence in PEGBIO CO-B's future prospects based on its technological R&D capabilities and progress in key clinical milestones. Second, market focus has been redirected to the company's circRNA-LNP technology platform after its core pipeline candidate, CR059, was selected as a Late Breaking Abstract at the American Diabetes Association's Scientific Sessions, highlighting the new possibilities of its ultra-long-acting GLP-1 technology pathway for metabolic diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1175159870","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175159870","pubTimestamp":1777442102,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.The sharp rise appears driven by two key positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|PEGBIO CO-B盘中大涨10.69%锁定延长及临床里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PEGBIO CO-B's stock surged 10.69% during intraday trading on Wednesday, marking a significant upward movement for the innovative drug company.The sharp rise appears driven by two key positive developments. First, the company announced that cornerstone investors have voluntarily agreed to extend their lock-up period, demonstrating strong confidence in PEGBIO CO-B's future prospects based on its technological R&D capabilities and progress in key clinical milestones. Second, market focus has been redirected to the company's circRNA-LNP technology platform after its core pipeline candidate, CR059, was selected as a Late Breaking Abstract at the American Diabetes Association's Scientific Sessions, highlighting the new possibilities of its ultra-long-acting GLP-1 technology pathway for metabolic diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175159870","isCrawlerRequest":true}